retatrutide ly3437943 parkinson's disease clinical trial (LY3437943), a Novel GIP/GLP-1/Glucagon Receptor Triagonist—Obesity, NAFLD, and T2D Phase 2 Results Triple hormone receptor agonist retatrutide

As cardiovascular risk climbs after menopause, we know that when we lose our estrogen, our risk for cardiovascular events goes up, up, up

Since then, it has become a popular option for diabetes management due to its once-weekly injections and ability to reduce the risk of cardiovascular events

For example, BPC-157 beginners start at 250 mcg/day, semaglutide beginners start at 0.25 mg/week, and CJC-1295/Ipamorelin beginners start at 100 mcg each per injection

By the first quarter of 2026, tirzepatide had become the most frequently prescribed agent at roughly 4,700 prescriptions per 100,000 patients, and semaglutide had grown to around 3,900 per 100,000

Best blood test for: Quick checks: Core Health Blood Test Weight loss checks: Weight Loss Blood Test In-depth checks: Advanced Well Woman Blood Test or Advanced Well Man Blood Test GLP-1 injection checks: Weight Loss Injection (GLP-1) Monitoring Blood Test References Geng J, Ni Q, Sun W, Li L, Feng X

One frequent error is injecting too quickly after cleaning the skin with alcohol